Copyright TechStartups.com
It’s Tuesday, November 11, 2025, and we’re back with the top startup and tech funding news stories making headlines today. From multilingual AI agents redefining enterprise communication to biotech breakthroughs and personalized AI clones, investors continued to back bold ideas reshaping the future of business, health, and data. Today’s highlights feature Wonderful, which raised $100 million at a $700 million valuation to scale culturally fluent AI agents for global enterprises; myTomorrows, which secured $29 million to expand access to life-saving experimental therapies; and CarboCode, which raised €15 million to commercialize human-identical milk lipids for infant and neurodegenerative treatments. The funding momentum also extended to fintech, ESG tech, and AI infrastructure, reflecting investors’ confidence in platforms that merge automation with tangible real-world impact. Funding Highlights Wonderful raised $100 million Series A to scale multilingual, culturally adaptive AI agents for enterprises. myTomorrows secured $29 million to expand its global platform connecting patients to early-access therapies. CarboCode raised €15 million Series C to scale human-identical milk lipids for infant and Alzheimer’s therapies. Arrived brought in $27 million to democratize single-family rental investing through fractional ownership. Crustdata raised $6 million to power real-time data streams for AI agents. Uare.ai secured $10.3 million to build evolving “Individual AIs” for creators and professionals. Accipiter Biosciences emerged with $12.7 million and pharma partnerships for AI-designed proteins. GreenFi raised $2 million to scale its AI-driven ESG risk management platform for corporates. Investor Activity Today’s rounds drew participation from some of the most active global investors, from Index Ventures and Insight Partners to Mayfield, Bessemer, and Neo, showing steady conviction in both frontier AI and practical automation. From biotech labs in Portugal to AI startups in Palo Alto and fintech hubs in Seattle, today’s funding activity underscores a global push toward smarter, more accessible, and culturally aware technology ecosystems. Here’s the full breakdown. Until tomorrow, have a great evening. Wonderful Raises $100 Million in Series A Funding to Scale Multilingual Enterprise AI Agents Wonderful, the Amsterdam-headquartered (R&D in Israel) startup building enterprise-grade multilingual AI agents across chat, voice, and email, today announced a $100 million Series A funding round led by Index Ventures, valuing the company at $700 million. The company is positioning itself as a category-defining player in “culturally fluent AI.” With traction across Europe and the Middle East and plans to expand into the Asia Pacific in 2026, Wonderful expects to hit $10 million ARR by year-end. Funds will scale hiring, deepen product architecture, and extend global reach. Founded in early 2025 by Bar Winkler and Roey Lalazar, Wonderful has built a platform that helps enterprises deploy and manage AI agents that can interact with customers across voice, chat, and email—in any language, and with cultural awareness baked in. These agents don’t just translate words; they adapt tone, phrasing, and behavior to match local customs, giving global companies a way to serve customers as if every market had its own team on the ground. Funding Details: Startup: Wonderful Investors: Index Ventures (lead), Insight Partners, IVP, Bessemer, Vine Ventures Amount Raised: $100 million Total Raised: ≈ $134 million Funding Stage: Series A Funding Date: November 11, 2025 Accipiter Biosciences Emerges with $12.7M in Seed Funding Round and Big Pharma Deals Seattle-based biotech startup Accipiter Biosciences unveiled a seed funding round of $12.7 million today, alongside announced partnerships with major pharmaceutical companies. The firm is focused on AI-designed proteins — harnessing machine learning to craft novel therapeutic molecules, and targeting what it describes as “undruggable” protein spaces. The capital will fuel further development of the AI protein design pipeline, scale internal lab capabilities, and enable early-stage therapeutic candidate advancement. The synergies with big pharma deals provide an important de-risking signal, suggesting that the startup is not just technology-only but has industry validation and potential commercialization pathways. Funding Details: Startup: Accipiter Biosciences Investors: Not fully listed (seed round with strategic pharma-industry participation) Amount Raised: $12.7 million Total Raised: Seed round (first major institutional) Funding Stage: Seed Funding Date: November 11, 2025 Uare.ai Raises $10.3 Million Seed to Build ‘Individual AI’ Platform Palo Alto-based Uare.ai (formerly Eternos.life) closed a $10.3 million seed led by Mayfield and Boldstart Ventures. The startup builds “Individual AIs” — personal digital models of a user’s knowledge, memories, and voice that evolve over time. The funds will expand engineering, launch beta pilots, and accelerate commercialization in the creator-economy segment. Co-founder & CEO team says personal AI will become a new productivity layer: a clone that can teach, mentor, and create while the original person sleeps. This round shows investor appetite shifting toward personalized AI experiences beyond corporate chatbots. Funding Details: Startup: Uare.ai Investors: Mayfield (lead), Boldstart Ventures, strategic investors Amount Raised: $10.3 million Total Raised: Seed only Funding Stage: Seed Funding Date: Nov 11, 2025 GreenFi Raises $2 Million in Seed Funding to Scale AI-Driven ESG Risk Platform Singapore-based GreenFi secured a $2 million seed round led by Transition VC to expand its AI-driven ESG risk-management platform for banks and corporates. GreenFi aggregates corporate disclosures, media sentiment, and environmental signals to detect sustainability risks in real time. Funds will go toward scaling operations in the U.S., Europe, and Asia, and enhancing its no-code AI tools. ESG tech remains investable when paired with automation and measurable ROI. GreenFi’s focus on compliance automation positions it well for regulators’ next wave of sustainability mandates. Funding Details: Startup: GreenFi Investors: Transition VC (lead), angel investors Amount Raised: $2 million Total Raised: Seed only Funding Stage: Seed Funding Date: Nov 11, 2025 Arrived Raises $27 Million in Growth Funding Round to Democratize Single-Family Rental Investing Seattle fintech startup Arrived — the “stock market for rental homes” — announced a $27 million growth round led by Neo, with participation from Forerunner Ventures, Bezos Expeditions, and Core VC. Arrived lets retail investors buy fractional shares of rental homes, once limited to institutional players. The funds will expand inventory, enhance liquidity features, and scale nationally. Fintech + real estate remains hot when backed by clear regulatory frameworks and scalable tech. Arrived’s approach to fractionalized property ownership may redefine how everyday investors access real assets. Funding Details: Startup: Arrived Investors: Neo (lead), Forerunner Ventures, Bezos Expeditions, Core VC Amount Raised: $27 million Total Raised: > $60 million Funding Stage: Growth / Platform expansion Funding Date: Nov 11, 2025 Crustdata Raises $6 Million Seed Round to Power Real-Time Data for AI Agents Crustdata, a Y Combinator-backed startup, raised $6 million in seed funding from A Capital, General Catalyst, SV Angel, and Phosphor Capital. The company builds real-time web-data infrastructure for AI agents, using proprietary crawlers to feed structured signals to sales, recruiting, and investment workflows. Revenue grew from $770K to $4 million within months — without outbound marketing. As AI agents proliferate, investors are funding the “data plumbing” layer — companies like Crustdata that ensure models stay fresh and relevant. Funding Details: Startup: Crustdata Investors: Y Combinator (lead), A Capital, General Catalyst, SV Angel, Phosphor Capital Amount Raised: $6 million Total Raised: Seed only Funding Stage: Seed Funding Date: Nov 11, 2025 CarboCode Raises €15 Million in Series C Funding to Scale Human-Identical Milk Lipids for Infant and Alzheimer’s Therapies Portugal-based biotech startup CarboCode has secured €15 million (~$16.2 million USD) in Series C funding led by Iberis Capital, bringing its total to €60 million. The company is pioneering the production of human-identical milk lipids — gangliosides — to close the nutritional gap between infant formula and natural breast milk. These lipids play a vital role in cognitive development and immunity, but have never been commercially produced at scale. CarboCode plans to finalize regulatory approvals in Europe and the U.S. by 2026, enter China by 2028, and reach industrial production of 100 tons per year by 2029 — enough to supply global formula leaders like Nestlé and Danone. Beyond infant nutrition, CarboCode sees therapeutic potential for Alzheimer’s and Parkinson’s disease, where declining ganglioside levels correlate with cognitive degeneration. CEO Jorge Santos, a veteran of Glycom A/S (acquired by DSM for $826 million), calls it “the next frontier of nutritional science.” With both the global infant-nutrition and dementia care markets exceeding €50 billion, CarboCode occupies a rare intersection of health, longevity, and biotech. Funding Details: Startup: CarboCode Investors: Iberis Capital (lead), existing backers Amount Raised: €15 million (~ $16.2 million USD) Total Raised: €60 million Funding Stage: Series C Funding Date: Nov 11, 2025 myTomorrows Raises $29 Million in Funding to Scale Global Access to Innovative Therapies Amsterdam-based health-tech company myTomorrows has raised $29 million in new funding to expand its platform that connects patients with serious or life-threatening conditions to innovative therapies that are still in development. The round, led by Avego, is aimed at scaling what the company describes as a “global access operating system” for pre-approval and early-access treatments. myTomorrows focuses on a problem that sits in the blind spot of traditional drug development: patients who cannot wait for full regulatory approval but may qualify for clinical trials, expanded access programs, or other controlled pathways. Over the past several years, the company has built technology and workflows that bring together patients, physicians, trial sites, regulators and biopharma sponsors under one coordinated process. According to the company, more than 16,000 patients across over 130 countries have already been supported through its platform. The new capital will be used to deepen the company’s technology stack, especially in areas such as workflow automation, decision support for physicians, and real-world data capture. myTomorrows also plans to grow its footprint in key therapeutic areas, including oncology, rare diseases, and neurology, where the gap between medical need and available treatments is often the widest. On the biopharma side, the company positions itself as a partner that can help sponsors manage access programs more efficiently while also generating structured evidence from real-world use. Funding Details: Startup: myTomorrows Investors: Avego (lead), with participation from other undisclosed investors Amount Raised: $29 million Total Raised: Not disclosed Funding Stage: Growth / Expansion Funding Date: November 11, 2025 Tech Funding Summary Table
